Results of the recent phase 3 LIFESPARK-005 trial showed that belzutifan was more effective than everolimus in treating advanced clear cell renal cell carcinoma when looking at progression-free survival (PFS) and objective response rate (ORR). In the trial, 746 patients previously treated with certain regimens were randomized to receive either belzutifan or everolimus. The belzutifan group had better PFS and ORR compared with the everolimus group, although overall survival did not differ significantly between the two. The final analysis of the trial will be presented in the future.
Reference: Benyon B. Improvement in Efficacy End Points Observed With Belzutifan in Clear Cell RCC. Published October 22, 2023. Accessed November 6, 2023. https://www.cancernetwork.com/view/improvement-in-efficacy-end-points-observed-with-belzutifan-in-clear-cell-rcc
